ATLASATLAS fair value
ATLAS has no fair value for this stock today.
First Tracks Biotherapeutics (TRAX)
First Tracks Biotherapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$45.38▲ +4.37%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on First Tracks Biotherapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On First Tracks Biotherapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives First Tracks Biotherapeutics a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $39.12 and $50.78; in 9 out of 10, between $31.04 and $63.99. Estimated annual volatility is 73%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.2B
- 52-week high
- $49.91
- 52-week low
- $14.72
- Revenue (12 months)
- $0.0M
- Return on equity
- -41.8%
- Free cash flow (12 months)
- $-164M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for TRAX right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks TRAX has traded between $14.72 and $49.91. Today it is 9.1% below that high and 208% above its low.
Its beta is 0.00: it tends to move less than the market.
About the company
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases.
Want to see everything about First Tracks Biotherapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does First Tracks Biotherapeutics do?
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases.
What is the chance TRAX goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, TRAX ends the month between $39.12 and $50.78.
How big is First Tracks Biotherapeutics and what is its P/E ratio?
First Tracks Biotherapeutics's market capitalization is $1.2B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is TRAX?
ATLAS estimates annual volatility at 73%. In a typical month, half of the outcomes end between $39.12 and $50.78.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer